Metrics to compare | SPARC | Peers Peers - average of corresponding metrics from companies closely matching SPARC: 6167, 8931, 600598, PRECWIRE, JYOTISTRUC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPARCPeersSector |
|---|---|---|---|---|
P/E Ratio | 3.8x | 16.7x | −0.2x | |
PEG Ratio | 0.01 | 0.42 | 0.00 | |
Price/Book | 4.4x | 2.3x | 2.6x | |
Price / LTM Sales | 3.2x | 2.2x | 2.8x | |
Upside (Analyst Target) | - | 11.8% | 65.6% | |
Fair Value Upside | Unlock | 1.8% | 10.0% | Unlock |
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.